5,578 results on '"EPSTEIN-Barr virus diseases"'
Search Results
2. Clinicopathologic Spectrum of Pediatric Posttransplant Lymphoproliferative Diseases Following Solid Organ Transplant.
- Author
-
Jinjun Cheng and Wistinghausen, Birte
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *TRANSPLANTATION of organs, tissues, etc. , *EPSTEIN-Barr virus diseases , *CELL proliferation , *IMMUNOTHERAPY , *SYMPTOMS , *LYMPHOMAS , *LYMPHOPROLIFERATIVE disorders , *GENETIC mutation , *MOLECULAR biology , *B cells , *IMMUNOSUPPRESSION , *DISEASE risk factors , *CHILDREN - Abstract
Context.--Posttransplant lymphoproliferative disorder (PTLD) remains a significant complication in pediatric patients undergoing solid organ transplant (SOT). The majority involve Epstein-Barr virus (EBV)-driven CD20+ B-cell proliferations, which respond to reduction of immuno-suppression and anti-CD20-directed immunotherapy. Owing to the low overall incidence, prospective studies of pediatric PTLD are scarce, leading to a lack of comprehensive under-standing of this disorder in pediatric populations. This review aims to bridge this knowledge gap by providing a comprehensive analysis of the clinical, morphologic, and molecular genetic features of PTLD in children, adolescents, and young adults after SOT. Objective.--To examine the clinical features, pathogenesis, and classification of pediatric PTLDs after SOT. Data Sources.--Personal experiences and published works in PubMed. Conclusions.--PTLD includes a broad and heterogeneous spectrum of disorders, ranging from nonmalignant lympho- proliferations to lymphomas. While most pediatric PTLDs are EBV+, an increasing number of EBV- PTLDs have been recognized. The pathologic classification of PTLDs has evolved in recent decades, reflecting advancements in understanding the underlying pathobiology. Nevertheless, there remains a great need for further research to elucidate the biology, identify patients at higher risk for aggressive dis-ease, and establish optimal treatment strategies for relapsed/ refractory disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Viral Co-Infection Diagnosis in Cervical Samples Using Next Generation Sequencing Technology.
- Author
-
Jumaa, Anfal Mohammed, Hwaid, Asmaa Haseeb, and Hasan, Abdulrazaq Shafiq
- Subjects
PAPILLOMAVIRUS diseases ,WOMEN ,CERVIX uteri tumors ,HIV ,GENOMICS ,EPSTEIN-Barr virus diseases ,HUMAN beings ,HIV infections ,DESCRIPTIVE statistics ,DNA ,PAP test ,IRAQIS ,MEDICAL screening ,DATA analysis software ,MIXED infections ,SEQUENCE analysis ,DISEASE risk factors - Abstract
Background & Objective: The study explores human papillomavirus (HPV), a significant cause of cervical cancer, and its potential coinfections with other viruses like human herpes virus type 4 (HHV-4) or Epstein-Barr virus (EBV) and HIV. Nextgeneration sequencing (NGS) technology is used to analyze viral content in cervical samples from Iraqi women. Materials & Methods: Eight cervical samples were collected and processed using Illumina DNA Prep on the iSeq100 System. Viral genomic DNA was isolated and libraries prepared for sequencing. Results: MetaviralSPAdes assembled contigs from each sample, which were then blasted against the NT database. HPV16, HHV4, HIV, and bovine alpha herpesvirus 5 were among the viruses identified across samples. Conclusion: Viral coinfections identified through NGS underscore their potential impact on cervical health, emphasizing NGS's diagnostic sensitivity for viral infections not typically detected by standard gynecological methods. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Clinical significance and different strategies for re-elevation of plasma EBV-DNA during treatment in pediatric EBV-associated hemophagocytic lymphohistiocytosis.
- Author
-
Wenzhi Zhang, Yun Peng, Yining Qiu, Li Cheng, Yuhong Yin, Ying Li, Lizhen Zhao, and Xiaoyan Wu
- Subjects
HEMOPHAGOCYTIC lymphohistiocytosis ,PEDIATRIC therapy ,HEMATOPOIETIC stem cell transplantation ,EPSTEIN-Barr virus diseases ,MUSCLE tumors ,THERAPEUTICS ,MACROPHAGE activation syndrome - Abstract
Objective: Monitoring the disease status of Epstein-Barr virus (EBV)-related hemophagocytic lymphohistiocytosis (HLH) patients is crucial. This study aimed to investigate the different strategies and outcomes of patients with EBV-HLH and re-elevated EBV-DNA. Method: A retrospective analysis was conducted on 20 patients diagnosed with EBV-HLH. Clinical features, laboratory tests, treatments, plasma EBV-DNA levels, and outcomes were assessed. Three cases were highlighted for detailed analysis. Results: Nine of the 20 patients had a re-elevation of EBV-DNA during treatment, and 55.5 % (5/9) experienced relapses. Patients with persistently positive plasma EBV-DNA (n = 4) and those with reelevated EBV-DNA after conversion (n = 9) showed a significantly higher relapse rate compared to those with persistently negative EBV-HLH (n = 7) (p < 0.05). Among the highlighted cases, Case 1 exhibited plasma EBV-DNA re-elevation after four weeks of treatment without relapse, maintaining stability with the original treatment regimen, and eventually, his plasma EBV-DNA turned negative. In Case 2, plasma EBV-DNA was elevated again with a recurrence of HLH after L-DEP. Consequently, she underwent allogeneic hematopoietic stem cell transplantation and eventually achieved complete remission (CR) with negative plasma EBV-DNA. Case 3 experienced plasma EBV-DNA re-elevation after L-DEP but remained in CR, discontinuing chemotherapy without relapse. Conclusion: The re-elevation of plasma EBV-DNA during EBV-HLH treatment poses challenges in determining disease status and treatment strategies. Optimal management decisions require a combination of the level of elevated EBV-DNA, the intensity of hyperinflammation, and the patient’s immune function. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Early predictors of Epstein-Barr virus infection in patients with severe fever with thrombocytopenia syndrome.
- Author
-
Pu, Qinqin, Dai, Yan, Hu, Nannan, Tao, Ziwei, Shi, Ping, Jiang, Nan, Shi, Luchen, Fang, Zegui, Wang, Ran, Hu, Xuehui, Jin, Ke, and Li, Jun
- Subjects
- *
EPSTEIN-Barr virus diseases , *BLOOD urea nitrogen , *RECEIVER operating characteristic curves , *IMMUNOGLOBULIN G , *C-reactive protein - Abstract
Background: Epstein-Barr virus (EBV) can be reactivated and proliferated with fatal outcome in immuno-compromised people, but the clinical consequences of EBV infection in patients with severe fever with thrombocytopenia syndrome (SFTS) remain uncertain. In this study, we investigated the infection rate, the influence and the early predictors of EBV infection in SFTS patients. Methods: In this retrospective study, SFTS patients who were treated in the First Affiliated Hospital of Nanjing Medical University from May 2011 to August 2021 were enrolled and divided into infected and non-infected groups. We compared the demographic characteristics, clinical manifestations and signs, laboratory tests and prognosis, and explored the risk factors of EBV infection by receiver operating characteristic (ROC) curve and logistic regression. Results: A total of 120 hospitalized SFTS patients with EBV-DNA testing were enrolled in this study. Patients with EBV infection had statistically significant higher mortality rate (32.0% vs. 11.43%, P = 0.005). Compared with the non-infected group, the EBV-infected group had higher levels of C-reactive protein (CRP), creatine-kinase (CK), fasting blood glucose (FBG), blood urea nitrogen (BUN), D-dimer, and CD56+ cell counts, lower levels of immunoglobulin G (IgG), IgM, complement 3 (C3), and C4. The proportion of patients with age ≥ 60 years and ferritin > 1500.0 ng/ml in the EBV-infected group was significantly higher than that in the non-infected group. The results of ROC analysis showed that the cut-off values of CRP, IgG, C3, C4, and CD56+ cell counts to predict EBV infection were 13.2 mg/l, 12.5 g/l, 1.1 g/l, 0.6 g/l, 0.3 g/l, and 94.0 cells/µl. Multivariable logistic analysis showed that age ≥ 60 years old, CRP > 13.2 mg/l, BUN > 5.4 mmol/l, ferritin > 1500.0 ng/ml, IgG < 12.5 g/l, IgM < 1.1 g/l, C4 < 0.3 g/l, and CD56+ cell counts > 94.0 cells/µl were the independent risk factors of EBV infection in SFTS patients. Conclusions: SFTS combined with EBV infection is associated with high morbidity and mortality. It is necessary to strengthen screening for EBV infection and its early predictive markers after admission in SFTS patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Epstein–Barr Viruses: Their Immune Evasion Strategies and Implications for Autoimmune Diseases.
- Author
-
Zhao, Yuehong, Zhang, Qi, Zhang, Botian, Dai, Yihao, Gao, Yifei, Li, Chenzhong, Yu, Yijing, and Li, Conglei
- Subjects
- *
SYSTEMIC lupus erythematosus , *INFECTION , *AUTOIMMUNE diseases , *LIFE cycles (Biology) , *EPSTEIN-Barr virus diseases , *EPSTEIN-Barr virus - Abstract
Epstein–Barr virus (EBV), a member of the γ-herpesvirus family, is one of the most prevalent and persistent human viruses, infecting up to 90% of the adult population globally. EBV's life cycle includes primary infection, latency, and lytic reactivation, with the virus primarily infecting B cells and epithelial cells. This virus has evolved sophisticated strategies to evade both innate and adaptive immune responses, thereby maintaining a lifelong presence within the host. This persistence is facilitated by the expression of latent genes such as EBV nuclear antigens (EBNAs) and latent membrane proteins (LMPs), which play crucial roles in viral latency and oncogenesis. In addition to their well-known roles in several types of cancer, including nasopharyngeal carcinoma and B-cell lymphomas, recent studies have identified the pathogenic roles of EBV in autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. This review highlights the intricate interactions between EBV and the host immune system, underscoring the need for further research to develop effective therapeutic and preventive strategies against EBV-associated diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Clinical utility of plasma Epstein-Barr virus DNA monitoring in pediatric Epstein‐Barr virus-associated hemophagocytic lymphohistiocytosis: a Chinese retrospective observational study.
- Author
-
Zhang, Wenzhi, Yin, Yuhong, Li, Ying, Cheng, Li, Zhao, Lizhen, Peng, Yun, and Wu, Xiaoyan
- Subjects
- *
HEMOPHAGOCYTIC lymphohistiocytosis , *VIRAL load , *RESEARCH funding , *RECEIVER operating characteristic curves , *EPSTEIN-Barr virus diseases , *SCIENTIFIC observation , *DNA , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *MEDICAL records , *ACQUISITION of data , *BLOOD plasma , *SENSITIVITY & specificity (Statistics) , *CHILDREN - Abstract
Background: Epstein-Barr virus DNA (EBV-DNA) is closely related to the pathogenesis and prognosis of EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH). The quantitative measurement of blood EBV-DNA is widely used in EBV-HLH, but there remains a lack of evidence to guide clinicians. Methods: A retrospective analysis was conducted on clinical manifestations, laboratory tests, 310 blood EBV-DNA loads, and prognosis of 51 pediatric patients diagnosed with EBV-HLH. Receiver operating characteristic (ROC) curves were utilized to determine the optimal cutoff values of EBV-DNA for predicting mortality and evaluating the active status of EBV-HLH. Results: EBV-positive- lymphoma-HLH had higher initial plasma EBV-DNA load(1.10 × 106copies/ml) compared to the EBV-HLH group (1.98 × 104 copies/ml) (P = 0.006), and experienced recurrently elevated plasma EBV-DNA levels during treatment. The optimal cut-off value of initial plasma EBV-DNA load in predicting mortality was 2.68 × 105 copies/ml, with a sensitivity of 88.57% and a specificity of 56.25%. For determining the active status of HLH, the optimal cutoff value of PBMC EBV-DNA load during treatment was 2.95 × 105 copies/ml, with a sensitivity of 69.14% and a specificity of 64.71%. The cut-off value of plasma EBV-DNA for determining active status was 1.32 × 103 copies/ml, with a sensitivity of 84.34%, and a specificity of 87.67%. Patients with higher PBMC and plasma EBV-DNA at initial and those with repeated elevated plasma EBV-DNA during treatment had worse prognoses (P < 0.05). Conclusion: Dynamic monitoring of EBV-DNA is a valuable tool for assessing disease status and predicting the prognosis of EBV-HLH, with plasma EBV-DNA being more effective than PBMC EBV-DNA. Patients with high levels of PBMC and plasma EBV-DNA at initial and those with repeated elevated plasma EBV-DNA during treatment had worse prognoses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Clinical Characteristics of Peripheral Lymphocyte Subtypes in Chronic Active Epstein-Barr Virus Infection.
- Author
-
Wei, Ang, Ou, Wenxin, Zhao, Yunze, Ma, Honghao, Zhang, Liping, Lian, Hongyun, Zhao, Xiaoxi, Zhang, Qing, Wang, Dong, Li, Zhigang, Wang, Tianyou, and Zhang, Rui
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *EPSTEIN-Barr virus diseases , *HEMOPHAGOCYTIC lymphohistiocytosis , *T cells , *POLYMERASE chain reaction - Abstract
Background We aimed to analyze the clinical characteristics of peripheral Epstein-Barr virus (EBV)-infected lymphocyte subtypes in children with chronic active EBV infection (CAEBV). Methods The levels of peripheral EBV infection of CD4+ T cells, CD8+ T cells, and CD56+ natural killer (NK) cells were determined by flow cytometry and quantitative polymerase chain reaction (qPCR) in patients with CAEBV from July 2017 to July 2022. Results In total, 112 children with CAEBV were evaluated. Of these, CD4+ type, CD8+ type, and CD56+ type were defined in 44, 21, and 47 patients, respectively. Patients with CD8+ T-cell type had a significantly higher frequency of rash, while hepatomegaly was more common in patients with CD4+ T-cell type. Generally, patients with CD8+ T-cell type had the lowest overall survival rate (P =.017). Patients treated with chemotherapy and hematopoietic stem cell transplantation (HSCT) had a better prognosis (P =.001). In multivariate analysis, rash, hemophagocytic lymphohistiocytosis, CD8+ T-cell type, and no decrease of plasma EBV-DNA after treatment were independent indicators of poor prognosis (P =.002,.024,.022, and.012, respectively). Conclusions In children with CAEBV, rash was more frequent in patients with CD8+ T-cell type, whereas patients with CD4+ T-cell type were more likely to develop hepatomegaly. Patients with CD8+ T-cell type had a poor prognosis despite receiving chemotherapy or further HSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Clinical epidemiology of Epstein-Barr virus-associated Lymphoproliferative Disorders (EBV-LPDs) in hospitalized children: A six-year multi-institutional study in China.
- Author
-
Dilmurat, Dilara, Wang, Xinyu, Gao, Liwei, Tian, Jiao, Ai, Junhong, Zhang, Linlin, Liu, Mengjia, Feng, Guoshuang, Zeng, Yueping, Wang, Ran, and Xie, Zhengde
- Subjects
- *
EXTRANODAL NK-T-cell lymphoma , *HEMOPHAGOCYTIC lymphohistiocytosis , *RESEARCH funding , *EPSTEIN-Barr virus diseases , *HOSPITAL care , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *CHILDREN'S hospitals , *HOSPITAL care of newborn infants , *MEDICAL records , *ACQUISITION of data , *RESEARCH , *LYMPHOPROLIFERATIVE disorders , *COMPARATIVE studies , *LENGTH of stay in hospitals , *MEDICAL care costs , *HOSPITAL care of children , *HOSPITAL care of teenagers , *DISEASE complications - Abstract
Background: Epstein-Barr virus-associated lymphoproliferative disorders (EBV-LPDs) are a group of disorders involving lymphoid tissues or lymphocytes. The epidemiology and economic burden of hospitalized children with EBV-LPDs in China have not been well studied. This study aimed to reveal the epidemic characteristics and disease burden of EBV-LPDs among the Chinese hospitalized children, providing strategies for the prevention and management. Methods: This study was based on the FUTang Updating medical REcords (FUTURE) database of China and collected the medical records from 27 tertiary children's hospitals between January 2016 and December 2021 in China, counting five types of EBV-LPDs, namely EBV-positive T-cell lymphoproliferative disease, NK/T cell lymphoma, extranodal NK/T-cell lymphoma (nasal type), systemic EBV-positive T-cell lymphoproliferative disease of childhood and posttransplant lymphoproliferative disorders. We conducted a retrospective syhthesis and analysis of the epidemiological characteristics, expenses, length of stay (LOS), as well as complications among hospitalized children diagnosed with five types of EBV-LPDs and compared parameters using appropriate statistical tests. Results: The study described 153 children aged 0–18 years hospitalized with EBV-LPDs from 2016 to 2021 in the FUTURE database. The male-to-female ratio was 1.10:1, and more than half of the age distribution was in the 6–12 y group. Among EBV-LPDs cases, EBV+ T-LPD accounted for the largest proportion (65.36%). Complications were presented in 93 children with EBV-LPDs, mainly hemophagocytic lymphohistiocytosis (HLH). The median LOS of NKTL was 26.5 days [interquartile range (IQR) = 3–42], which was the longest among EBV-LPDs. The median hospitalization cost of PTLD was 10 785.74 United States dollars (IQR = 7 329.38–16 531.18), which was the heaviest among EBV-LPDs. Conclusions: Compared with the total number of hospitalized children in China during the same period and in the same age group, the proportion of EBV-LPD is very low. EBV-LPD can develop in all age groups, but it is more common in school-age children. Among 5 EBV-LPDs, the disease with the highest proportion is EBV+ T-LPD. The overall disease burden of EBV-LPD was heavy, especially the economic burden. HLH was one of the most common complications, which could directly affect the burden of patients because of prolonged hospitalization. These data are taken from a very large database, illustrating the epidemiological and economic burden of EBV-LPDs hospitalized children in China, which enriched the existing epidemiological and disease burden content of EBV-LPDs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant.
- Author
-
Cao, Yaqing, Shang, Jingjing, Zhai, Yingying, Wang, Qingyuan, Yan, Lingzhi, Shi, Xiaolan, Wang, Jing, Yao, Ying, Zhou, Huifen, Sun, Aining, Miao, Miao, Fu, Chengcheng, and Jin, Song
- Subjects
- *
MULTIPLE myeloma , *PLASMACYTOMA , *BONE marrow , *MONOCLONAL gammopathies , *TREATMENT effectiveness , *EPSTEIN-Barr virus diseases , *THALIDOMIDE - Abstract
This article discusses a rare case of plasma cell myeloma, a type of cancer, occurring after a bone marrow transplant. The patient, a 48-year-old male, developed the condition after receiving a stem cell transplant for acute myeloid leukemia. The cancer was found to be positive for the Epstein-Barr virus (EBV), and the patient was successfully treated with a combination of bortezomib, thalidomide, and dexamethasone. The treatment resulted in a very good partial response, and the patient has remained disease-free for over three years. The article highlights the rarity of this condition and the need for further research and treatment protocols. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
11. Generalized lymphadenopathy in the presence of acute Epstein–Barr virus infection as the initial manifestation of systemic lupus erythematous: A case report.
- Author
-
Jazi, Kimia, Faraji, Zahra, Aghaei, Fateme, Shahhamzeh, Alireza, Tabaraii, Reihane, and Masoumi, Maryam
- Subjects
- *
EPSTEIN-Barr virus diseases , *LYMPHADENITIS , *DELAYED diagnosis , *VIRUS diseases , *SACROILIITIS , *AUTOIMMUNE diseases - Abstract
Key Clinical Message: Clinicians should carefully consider generalized lymphadenopathy, particularly post viral infections, as one of the possible systemic lupus erythematous (SLE) first signs regarding unusual joint involvements such as sacroiliitis. Late diagnosis of this autoimmune inflammatory disease, could lead to irreversible morbidity and higher mortality. Lymphadenopathy could represent various etiologies, including infections, malignancies, and rheumatologic diseases. SLE is known as the great mimicker which could be presented with different first manifestations. We report a 42‐year‐old woman in the acute phase of Epstein–Barr infection, admitted with polyarticular peripheral arthritis, sacroiliitis, and generalized lymphadenopathy. She had no similar history or taken unpasteurized dairy. Nodes were soft, mobile, and tender without skin change on top. During the process, she was diagnosed with SLE and discharged with prednisolone 30 mg/day and hydroxychloroquine 400 mg/day. After 2 weeks of follow‐up, all lymphadenopathy and symptoms were diminished. This case underscores the thousand faces innate of SLE. Clinical awareness would lead to an accurate diagnosis and early intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Chronic active Epstein-Barr virus infection with reinfection of SARS-CoV-2: a case report.
- Author
-
Wu, Hongmei, Liu, Li, Qu, Jialin, Wang, Chunrui, Shi, Xiaofeng, and Lei, Yu
- Subjects
- *
EPSTEIN-Barr virus diseases , *SARS-CoV-2 , *VIRUS diseases , *REINFECTION , *LIVER enzymes - Abstract
We describe the case of a 57-year-old male with jaundice, abdominal distension and fatigue. He was diagnosed as chronic active Epstein-Barr virus infection (CAEBV) due to intermittent elevated liver enzymes, hepatosplenomegaly and pancytopenia, with persistent positive of EBV biomarkers in blood and also positive in liver tissue. The patient was reinfected by SARS-CoV-2 within 2 months companied with CAEBV. The patient's second infection with SARS-CoV-2 led to the aggravated liver dysfunction with pneumonia and re-admission. After receiving symptomatic treatment, the patient showed significantly improvement of symptoms with partially restoration of liver function. After discharge, the patient's health status continued to deteriorate and eventually died. The instances of SARS-CoV-2 co-infection with the original chronic virus are not uncommon, but the exact mechanism of EBV and SARS-CoV-2 coinfection and the relationship between them are still unclear. Since co-infection of SARS-CoV-2 with original chronic virus might affect each other and lead disease aggravated and complicated, it is necessary to differentiate in the diagnosis of disease and it is important to be aware of the re-infection signs of SARS-CoV-2 in people with chronic virus infection diseases, as well as the risk of co-infection of SARS-CoV-2 with other viruses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Evaluation of novel Epstein-Barr virus-derived antigen formulations for monitoring virus-specific T cells in pediatric patients with infectious mononucleosis.
- Author
-
Fischer, Franziska, Mücke, Johannes, Werny, Louisa, Gerrer, Katrin, Mihatsch, Lorenz, Zehetmaier, Stefanie, Riedel, Isa, Geisperger, Jonas, Bodenhausen, Maren, Schulte-Hillen, Lina, Hoffmann, Dieter, Protzer, Ulrike, Mautner, Josef, Behrends, Uta, Bauer, Tanja, and Körber, Nina
- Subjects
- *
T cells , *MONONUCLEOSIS , *CHILD patients , *ANTIGENS , *VIRAL proteins , *EPSTEIN-Barr virus diseases - Abstract
Background: Infection with the Epstein-Barr virus (EBV) elicits a complex T-cell response against a broad range of viral proteins. Hence, identifying potential differences in the cellular immune response of patients with different EBV-associated diseases or different courses of the same disorder requires interrogation of a maximum number of EBV antigens. Here, we tested three novel EBV-derived antigen formulations for their ability to reactivate virus-specific T cells ex vivo in patients with EBV-associated infectious mononucleosis (IM). Methods: We comparatively analyzed EBV-specific CD4+ and CD8+ T-cell responses to three EBV-derived antigen formulations in 20 pediatric patients during the early phase of IM: T-activated EBV proteins (BZLF1, EBNA3A) and EBV-like particles (EB-VLP), both able to induce CD4+ and CD8+ T-cell responses ex vivo, as well as an EBV-derived peptide pool (PP) covering 94 well-characterized CD8+ T-cell epitopes. We assessed the specificity, magnitude, kinetics, and functional characteristics of EBV-specific immune responses at two sequential time points (v1 and v2) within the first six weeks after IM symptom onset (Tonset). Results: All three tested EBV-derived antigen formulations enabled the detection of EBV-reactive T cells during the early phase of IM without prior T-cell expansion in vitro. EBV-reactive CD4+ and CD8+ T cells were mainly mono-functional (CD4+: mean 64.92%, range 56.15-71.71%; CD8+: mean 58.55%, range 11.79-85.22%) within the first two weeks after symptom onset (v1) with IFN-γ and TNF-secreting cells representing the majority of mono-functional EBV-reactive T cells. By contrast, PP-reactive CD8+ T cells were primarily bi-functional (>60% at v1 and v2), produced IFN-γ and TNF and had more tri-functional than mono-functional components. We observed a moderate correlation between viral load and EBNA3A, EB-VLP, and PP-reactive CD8+ T cells (rs = 0.345, 0.418, and 0.356, respectively) within the first two weeks after Tonset, but no correlation with the number of detectable EBV-reactive CD4+ T cells. Conclusions: All three EBV-derived antigen formulations represent innovative and generic recall antigens suitable for monitoring EBV-specific T-cell responses ex vivo. Their combined use facilitates a thorough analysis of EBV-specific T-cell immunity and allows the identification of functional T-cell signatures linked to disease development and severity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. A Case of Unilateral Vision Loss Due to Optic Disc Infiltration by Sarcoidosis.
- Author
-
Denson, Rebecca S. and Bateman, Kristin M.
- Subjects
- *
SARCOIDOSIS , *IRIDOCYCLITIS , *OPTIC disc , *VISION disorders , *EPSTEIN-Barr virus diseases , *NEEDLE biopsy , *OPTIC disc edema - Abstract
This article presents a case study of a young woman who suffered sudden vision loss in her left eye. The article explores the various potential causes of her condition, including lymphoma, multiple sclerosis, stroke, and other eye-related conditions. Through laboratory tests and imaging studies, the doctors were able to diagnose the patient with sarcoidosis, a condition characterized by the development of non-caseating granulomas in different organs. The article highlights the importance of considering sarcoidosis as a possible cause of vision loss, even in the absence of other symptoms. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
15. Epstein–Barr Virus and Clinico-Endoscopic Characteristics of Gastric Remnant Cancers Compared to Proximal Non-Remnant Cancers: A Population-Based Study.
- Author
-
Bringeland, Erling A., Våge, Christina, Ubøe, Ann A. S., Sandø, Alina D., Mjønes, Patricia, and Fossmark, Reidar
- Subjects
- *
ADENOCARCINOMA , *GASTRECTOMY , *STOMACH tumors , *GASTROINTESTINAL hemorrhage , *STATISTICAL significance , *RESEARCH funding , *EPSTEIN-Barr virus diseases , *ENDOSCOPIC surgery , *SYMPTOMS , *MANN Whitney U Test , *CHI-squared test , *DESCRIPTIVE statistics , *EPSTEIN-Barr virus , *KAPLAN-Meier estimator , *LOG-rank test , *TUMORS , *DATA analysis software , *ENDOSCOPY , *DISEASE complications - Abstract
Simple Summary: Epstein–Barr virus (EBV)-associated gastric cancer is accepted as a distinct entity among gastric adenocarcinomas. It is particularly frequent in gastric remnant cancer (GCR), defined as cancer in the gastric stump several decades after distal gastric resection for benign disease. Gastric cancer in the West is a comparatively rare disease, and most of the published data stem from the East. Using population-based data from the West spanning the years from 2001 to 2016, we were able to show that a significantly higher proportion of GRCs compared to non-GRC proximally located cancers were EBV-positive, even in the West. The mode of presentation and findings at upper endoscopy were more subtle and differed significantly from proximally located non-GRC cancers, possibly making the GRCs more difficult to diagnose. Epstein–Barr virus (EBV) is associated with 5–10% of gastric cancers and is recognized as a distinct molecular subtype. EBV positivity is particularly high in gastric remnant cancer (GRC), which may inform the mode of clinical presentation and findings at endoscopy. Most data are from the East, and the question remains how this applies to a Western cohort. We conducted a population-based study in Central Norway, 2001–2016. Patients with GRC (n = 78) and patients with non-GRC proximally located cancer and available tissue for EBV status (n = 116, control group) were identified from the Norwegian Cancer Registry. Relevant data were collected from the individual patient journals. EBV status was assessed using in situ hybridization. The median latency time from the distal gastrectomy to GRC was 37.6 (range 15.7–68.0) years. GRC more often presented with GI bleeding, 31.0% vs. 16.1%, p = 0.017, and at endoscopy more seldom with an ulcer, 19.7% vs. 38.2%, p = 0.012, or a tumour, 40.8% vs. 66.4%, p < 0.001. For GRC, 18.7% were EBV-positive compared to 6.0% among the controls, p = 0.006. EBV status was not associated with patient age, sex, or Lauren histological type. No difference in long-term survival rates between GRC and controls was found or between EBV-positive vs. -negative GRCs. In conclusion, a higher proportion of GRC cases, compared to controls, are EBV positive, indicating different causative factors. The mode of clinical presentation and findings at endoscopy were more subtle in the patients with GRC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Lipschütz Syndrome: Not All Genital Ulcers Are Herpes.
- Author
-
Lerner, Henry Michael
- Subjects
- *
ULCER diagnosis , *FEMALE reproductive organ diseases , *VULVAR diseases , *ANTI-inflammatory agents , *ULCERS , *EPSTEIN-Barr virus diseases , *RARE diseases , *VULVODYNIA , *POLYMERASE chain reaction , *OINTMENTS , *FEVER , *HYGIENE , *BETAMETHASONE , *URINARY catheters , *DYSURIA , *LIDOCAINE - Abstract
The article presents the discussion on case study of 10-year-old girl with vulvar herpes ulcers. Topics include young patient and her mother have received skeptical responses from the emergency department physician and the pediatrician who have seen her; and frequency of Lipschütz ulcers is uncertain as the condition is often misdiagnosed, and patients with it are usually seen in outpatient facilities.
- Published
- 2024
- Full Text
- View/download PDF
17. Current perspectives on Multiple Sclerosis.
- Author
-
ÇİMEN, Sema and KÜÇÜKOĞLU, Kaan
- Subjects
EPSTEIN-Barr virus diseases ,GLATIRAMER acetate ,DIMETHYL fumarate ,NEUROLOGICAL disorders ,SYMPTOMS - Abstract
Multiple Sclerosis (MS) is a chronic, autoimmune disease that affects the central nervous system. It is characterized by inflammation, demyelination and axonal loss, and is typically manifested by relapses and remissions. It is the most prevalent neurological disorder worldwide, with a significant prevalence in many countries. It is the leading cause of non-traumatic neurological impairment in young adults. Although the etiology is not fully understood, genetic predisposition, environmental factors (exposure to inadequate sunlight and/or inadequate dietary intake of vitamin D, Epstein-Barr virus infection, etc.) Furthermore, an individual's lifestyle, including obesity, smoking, and other factors, plays a significant role in the development of the disease. The clinical subtypes of MS, as defined in 2013, are classified into four categories: The four main clinical subtypes of MS are: Isolated Syndrome, Relapsing-Remitting MS, Primary Progressive MS and Secondary Progressive MS. The clinical subtypes of MS are further subdivided according to the activity and progression of the disease. MS is a heterogenous disease, with lesions affecting multiple systems. The most common clinical manifestations include fatigue, blurred vision, and ocular pain (optic neuritis), as well as weakness and sensory changes in specific body regions, such as the face, arms, and legs. Furthermore, the patient presented with symptoms including balance impairment, vertigo, memory and cognitive difficulties, and bladder control issues. Although there is currently no cure for MS, existing treatments focus on alleviating acute attacks, improving symptoms, and reducing the impact of the disease through biological therapies. Modifying therapies for the disease (e.g., interferons, glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod, ocrelizumab, natalizumab, etc.) These drugs, which reduce the frequency of clinical attacks and slow the progression of the disease, also reduce the activity of MRI lesions, making them an important component of MS treatment. They are effective due to their diverse mechanisms of action, administration routes, and dosages. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Point-of-Care Immunosensor for Epstein-Barr Virus Infection Detection Using a Biocarbon-based Platform.
- Author
-
Chen Chen and Meiling Liu
- Subjects
EPSTEIN-Barr virus diseases ,EPSTEIN-Barr virus ,RESOURCE-limited settings ,POINT-of-care testing ,POLYMERASE chain reaction ,DETECTION limit - Abstract
We present the development of a novel point-of-care electrochemical immunosensor for the detection of the Epstein-Barr virus capsid antigen (EBVCA-IgA) using a biocarbon-modified screen-printed electrode platform. The biosensor achieves sensitive and rapid detection within a broad linear range of 0.1 pM to 10 nM of EBVCA-IgA, with an impressive limit of detection of 33 fM. The key to its practical utility is that the sensor operates efficiently, providing results in under one hour, which is a significant improvement over traditional methods such as enzymelinked immunosorbent assays and polymerase chain reaction that typically exceed two hours. We also emphasize the sensor's high selectivity by demonstrating minimal cross-reactivity with other common respiratory viruses. With its combination of rapidity, sensitivity, and simplicity, this biosensor represents a significant advancement in Epstein-Barr virus (EBA) diagnostics, which makes it particularly beneficial in clinical and low-resource settings where rapid and reliable testing is paramount. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Combined treatment with allogeneic Epstein–Barr- and human polyomavirus 1 specific T-cells in progressive multifocal leukoencephalopathy and EBV infection: a case report.
- Author
-
Nay, Sandra, Möhn, Nora, Grote-Levi, Lea, Bonifacius, Agnes, Saßmann, Mieke L., Karacondi, Kevin, Tischer-Zimmermann, Sabine, Pöter, Henning, Mahmoudi, Nima, Wattjes, Mike P., Maecker-Kolhoff, Britta, Höglinger, Günter, Eiz-Vesper, Britta, and Skripuletz, Thomas
- Subjects
EPSTEIN-Barr virus diseases ,POLYOMAVIRUS diseases ,T cells ,PROGRESSIVE multifocal leukoencephalopathy ,OPPORTUNISTIC infections - Abstract
Opportunistic viral infections in individuals with severe immunodeficiency can lead to fatal conditions such as progressive multifocal leukoencephalopathy (PML), for which treatment options are limited. These infections pose significant risks, especially when co-infections with other viruses occur. We describe a combined therapy approach using directly isolated allogeneic Human Polyomavirus 1 (also known as BKV) and Epstein–Barr virus (EBV) specific cytotoxic T-cells for the treatment of PML in conjunction with identified EBV in the cerebrospinal fluid (CSF) of a male patient infected with human immunodeficiency virus (HIV). A 53-year-old HIV-positive male, recently diagnosed with PML, presented with rapidly worsening symptoms, including ataxia, tetraparesis, dysarthria, and dysphagia, leading to respiratory failure. The patient developed PML even after commencing highly active antiretroviral therapy (HAART) 3 months prior. Brain magnetic resonance imaging (MRI) revealed multifocal demyelination lesions involving the posterior fossa and right thalamus suggestive of PML. In addition to the detection of human polyomavirus 2 (also known as JCV), analysis of CSF showed positive results for EBV deoxyribonucleic acid (DNA). His neurological condition markedly deteriorated over the following 2 months. Based on MRI, there was no evidence of Immune Reconstitution Inflammatory Syndrome contributing to this decline. The patient did not have endogenous virus-specific T-cells. We initiated an allogeneic, partially human leukocyte antigen-matched transfer of EBV and utilizing the cross-reactivity between BKV and JCV–BKV specific T-cells. This intervention led to notable neurological improvement and partial resolution of the MRI lesions within 6 weeks. Our case of a patient with acquired immune deficiency syndrome demonstrates that PML and concurrent EBV co-infection can still occur despite undergoing HAART treatment. This innovative experimental therapy, involving a combination of virus-specific T-cells, was demonstrated to be an effective treatment option in this patient. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Epstein-Barr virus seroprevalence among inflammatory bowel disease patients in Saudi Arabia.
- Author
-
Al-Bawardy, Badr, Alfadley, Abdulaziz F., Almousallam, Mohammed, AlShathri, Saad, Aboueissa, Mohamed, Alsulaiman, Abdulrahman, Attamimi, Mashary, and AlMutairdi, Abdulelah
- Subjects
- *
INFLAMMATORY bowel disease diagnosis , *VIRAL antibodies , *PEARSON correlation (Statistics) , *MESALAMINE , *IMMUNOSUPPRESSIVE agents , *T-test (Statistics) , *CROHN'S disease , *EPSTEIN-Barr virus diseases , *METHOTREXATE , *TERTIARY care , *RETROSPECTIVE studies , *CHI-squared test , *SEROCONVERSION , *DESCRIPTIVE statistics , *ULCERATIVE colitis , *INFLAMMATORY bowel diseases , *EPSTEIN-Barr virus , *RESEARCH , *SEROPREVALENCE - Abstract
Background: Seroprevalence of Epstein-Barr virus (EBV) in patients with inflammatory bowel disease (IBD) is variable based on geographic distribution. There are no published data on the seroprevalence of EBV in patients with IBD in Saudi Arabia. This study aims to assess the seroprevalence of EBV in patients with IBD in a tertiary center in Saudi Arabia. Methods: This is a retrospective chart review of patients ≥14 years of age with a confirmed diagnosis of IBD and known EBV status at our institution from January 1, 2018, to January 1, 2023. The primary outcome was the seroprevalence of EBV in IBD. Secondary outcomes included factors associated with EBV seropositivity and rates of EBV seroconversion in originally negative patients. Results: A total of 150 patients were included (74.7% with Crohn's disease, median age 28 years [interquartile range 21-36.3]). EBV non-exposure was noted in 16.8% (n = 25). The mean age was significantly lower in the EBV-naïve group at 26 ± 8.5 years compared to the EBV-exposed group at 31.2 ± 12.9 years (P = 0.02). Seroprevalence of EBV was highest in patients >40 years of age (92.9%) and lowest in patients 14-25 years of age (78.2%). The rate of seroconversion in EBV-naïve patients was 16.7% after a mean follow-up time of 47.9 ± 46.3 months. Conclusion: In our cohort of IBD patients, 16.8% were naïve to EBV, and young age was a significant predictor of EBV non-exposure. Our data supports the practice of assessing EBV before initiating thiopurine therapy since EBV seroprevalence is not universal in our population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Fever with Rash in a Child: Revisited.
- Author
-
Sarkar, Rashmi, Yadav, Anukriti, and Maheshwari, Apoorva
- Subjects
- *
DIFFERENTIAL diagnosis , *EARLY medical intervention , *STAPHYLOCOCCAL diseases , *STEVENS-Johnson Syndrome , *EXANTHEMA , *MEASLES , *TOXIC epidermal necrolysis , *SCARLATINA , *SCHOENLEIN-Henoch purpura , *EPSTEIN-Barr virus diseases , *FEVER , *DENGUE , *DRESS syndrome , *SYSTEMIC lupus erythematosus , *CHIKUNGUNYA , *RUBELLA , *RICKETTSIAL diseases , *TOXIC shock syndrome , *CHICKENPOX , *MONKEYPOX , *JOINT pain , *DRUG eruptions , *ACRODERMATITIS , *MUCOCUTANEOUS lymph node syndrome , *PARVOVIRUS diseases , *HAND, foot & mouth disease , *COVID-19 , *TYPHOID fever , *CHILDREN - Abstract
Rash and fever are some of the most common chief complaints present in paediatric dermatology emergencies. The spectrum of differential diagnosis is broad, including many different infectious and some non-infectious agents. A systematic approach involving detailed history taking, careful clinical examination along with particular attention to epidemiological features are the most important factors to make a diagnosis. This article reviews the morphological patterns of various causes of fever with rash in children, including infectious as well as non-infectious causes, with special emphasis on the Indian scenario. We intend to highlight the clinical characteristics of each cause, which will not only help make a clinical diagnosis but also distinguish benign versus life-threatening causes of skin rash in febrile paediatric patients and provide early medical intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Secondary hemophagocytic lymphohistiocytosis in pediatric patients with visceral leishmaniasis and Epstein-Barr virus infection.
- Author
-
Li, Yuanfang, Li, Sanjing, Lu, Nadan, Wang, Weilin, and Wang, Dao
- Subjects
- *
CHILD patients , *HEMOPHAGOCYTIC lymphohistiocytosis , *EPSTEIN-Barr virus diseases , *VISCERAL leishmaniasis , *MACROPHAGE activation syndrome ,BONE marrow examination - Abstract
Visceral leishmaniasis-associated hemophagocytic lymphohistiocytosis (VL-HLH) is indistinguishable from those of HLH of other etiologies due to the overlap symptoms, posing a serious threat to life. In this study, we aimed to provide insights for early diagnosis and improve outcomes in pediatric patients with VL-HLH. We retrospectively analyzed the clinical and laboratory data of 10 pediatric patients with VL-HLH and 58 pediatric patients with Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH). The median time from symptom onset to cytopenia in patients with VL-HLH and EBV-HLH was 11 days (interquartile range, 7–15 days) and five days (interquartile range, 3.75–9.25 days) (P = 0.005). Both groups showed liver injury and increased lactate dehydrogenase levels; however the levels of aspartate aminotransferase, alanine aminotransferase, direct bilirubin, and lactate dehydrogenase in patients with VL-HLH were significantly lower than those in patients with EBV-HLH (P < 0.05). The fibrinogen and triglyceride levels were almost normal in VL-HLH patients but were significantly altered in EBV-HLH cases (P < 0.05). The positive rate of first bone marrow microscopy examination, anti-rK39 IgG detection, and blood metagenomic next-generation sequencing was 50%, 100%, and 100%, respectively. After VL diagnosis, eight patients were treated with sodium stibogluconate and two were treated with liposomal amphotericin B. All the patients with VL-HLH recovered. Our study demonstrates that regular triglyceride and fibrinogen levels in pediatric patients with VL-HLH may help in differential diagnosis from EBV-HLH. VL-HLH is milder than EBV-HLH, with less severe liver injury and inflammatory responses, and timely treatment with antileishmanial agents is essential to improve the outcomes of pediatric patients with VL-HLH. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Characteristics of Virology and Immune Inflammation of Epstein-Barr Virus Infection Related Non-Neoplastic Diseases in Children.
- Author
-
Qin Wang, Zhi Duan, Wanlu Duan, Mengqi Ruan, Yunyun Zhang, Hao Zhang, and Qiang Zhou
- Subjects
EPSTEIN-Barr virus diseases ,JUVENILE diseases ,LYMPHOCYTE subsets ,MONONUCLEOSIS ,LYMPHOCYTE count ,HEMOPHAGOCYTIC lymphohistiocytosis ,DISEASE relapse - Abstract
Background: The goal was to study the difference of virological, immunologic, and inflammatory indicators between Epstein-Barr associated infectious mononucleosis (EBV-IM) and EBV associated hemophagocytic lymphohistiocytosis (EBV-HLH) and to explore the evaluation indicators for monitoring the therapeutic efficacy of EBVHLH. Methods: Twenty children with EBV-IM (IM group) and 10 children with EBV-HLH (HLH group) were selected. Virology indicators were detected; the absolute count of lymphocyte, and lymphocyte subsets were detected; the levels of immunoglobulin and ferritin were assayed. Results: Compared to the IM group, the HLH group showed a decrease in EBV-specific VCA-IgM antibody levels (U = 29.0, p = 0.006) and an increase in EBV-specific NA-IgG antibody levels (U = 17.0, p = 0.001), while there was no significant difference in EB-DNA loads (t = 0.417, p = 0.680). The counts of lymphocytes, and various lymphocyte subsets in the HLH group were lower than those in the IM group. Inflammatory markers in the HLH group were significantly higher than those in IM group. Dynamic monitoring of virological, immunological, and inflammatory indicators in HLH patients during treatment showed that EBV DNA gradually decreased in patients with good prognosis. Inflammatory indicators significantly decreased and returned to normal, lymphocyte count significantly increased and returned to normal during treatment. However, patients with poor prognosis showed rebound increase in EBV DNA and inflammatory indicators in the later stage of treatment, while lymphocyte count further decreased with the recurrence of the disease. Conclusions: Exhausted and damaged immune function in host by persistent stimulation of EB viral antigen is one of the main pathogeneses of EB-HLH. Lymphocyte count and serum ferritin level are effective indicators to monitor the therapeutic efficacy during the treatment to HLH. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Inflammatory Markers in Children and Adolescents with Functional Somatic Disorders: A Systematic Review.
- Author
-
Hansen, Anne Sofie, Rask, Charlotte Ulrikka, and Kallesøe, Karen Hansen
- Subjects
SOMATOFORM disorders ,RISK assessment ,MEDICAL information storage & retrieval systems ,IRRITABLE colon ,EPSTEIN-Barr virus diseases ,ABDOMINAL pain ,SYSTEMATIC reviews ,MEDLINE ,SERUM ,BLOOD plasma ,MONONUCLEOSIS ,INFLAMMATION ,ONLINE information services ,CYTOKINES ,CHRONIC fatigue syndrome ,BIOMARKERS ,PSYCHOLOGY information storage & retrieval systems ,INTERLEUKINS ,C-reactive protein ,TUMOR necrosis factors ,NOSOLOGY ,DISEASE risk factors ,ADOLESCENCE ,CHILDREN - Abstract
Functional somatic disorders (FSDs) are common in children and adolescents. Recent findings suggest that low-grade inflammation has a role in the development and maintenance of pediatric FSDs. This systematic review included studies with original data on systemic inflammatory markers in children and adolescents with an FSD compared to individuals without an FSD. The literature search identified 1374 articles. After assessment, a total of 15 studies met the inclusion criteria. In total, 41 serum or plasma cytokines were assayed in a population of 696 children and adolescents. Altered cytokine levels in patients with FSDs were reported in 12 studies, whereas three studies found no significant differences when comparing patients with FSDs and controls. The cytokine levels were significantly elevated in nine studies (i.e., IL-2, IL-6, IL-8, IL-12 (p70), CRP, hsCRP, IP-10, MCP-1, sTIM-3, sCD25 and TNF- α ). The findings indicate that inflammatory response may have a role in the pathophysiology of pediatric FSDs. However, the included studies showed limited quality with potential risk of bias, small study populations and a narrow spectrum of included FSDs, which limits the generalizability of the results. To further explore the potential link between inflammatory markers and pediatric FSDs, future research using a longitudinal study design is recommended. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice.
- Author
-
Bristol, Jillian A., Nelson, Scott E., Ohashi, Makoto, Casco, Alejandro, Hayes, Mitchell, Ranheim, Erik A., Pawelski, Abigail S., Singh, Deo R., Hodson, Daniel J., Johannsen, Eric C., and Kenney, Shannon C.
- Subjects
- *
LATENT infection , *B cells , *EPSTEIN-Barr virus diseases , *CORD blood , *GENE expression , *PROTEIN expression , *BCL genes - Abstract
Epstein-Barr virus (EBV) is an important cause of human lymphomas, including Burkitt lymphoma (BL). EBV+ BLs are driven by Myc translocation and have stringent forms of viral latency that do not express either of the two major EBV oncoproteins, EBNA2 (which mimics Notch signaling) and LMP1 (which activates NF-κB signaling). Suppression of Myc-induced apoptosis, often through mutation of the TP53 (p53) gene or inhibition of pro-apoptotic BCL2L11 (BIM) gene expression, is required for development of Myc-driven BLs. EBV+ BLs contain fewer cellular mutations in apoptotic pathways compared to EBV-negative BLs, suggesting that latent EBV infection inhibits Myc-induced apoptosis. Here we use an EBNA2-deleted EBV virus (ΔEBNA2 EBV) to create the first in vivo model for EBV+ BL-like lymphomas derived from primary human B cells. We show that cord blood B cells infected with both ΔEBNA2 EBV and a Myc-expressing vector proliferate indefinitely on a CD40L/IL21 expressing feeder layer in vitro and cause rapid onset EBV+ BL-like tumors in NSG mice. These LMP1/EBNA2-negative Myc-driven lymphomas have wild type p53 and very low BIM, and express numerous germinal center B cell proteins (including TCF3, BACH2, Myb, CD10, CCDN3, and GCSAM) in the absence of BCL6 expression. Myc-induced activation of Myb mediates expression of many of these BL-associated proteins. We demonstrate that Myc blocks LMP1 expression both by inhibiting expression of cellular factors (STAT3 and Src) that activate LMP1 transcription and by increasing expression of proteins (DNMT3B and UHRF1) known to enhance DNA methylation of the LMP1 promoters in human BLs. These results show that latent EBV infection collaborates with Myc over-expression to induce BL-like human B-cell lymphomas in mice. As NF-κB signaling retards the growth of EBV-negative BLs, Myc-mediated repression of LMP1 may be essential for latent EBV infection and Myc translocation to collaboratively induce human BLs. Author summary: EBV is a human gamma herpesvirus that causes infectious mononucleosis and cooperates with translocation of the Myc oncogene to induce Burkitt lymphoma (BL). EBV-infected BLs are derived from germinal center B cells and contain highly latent forms of EBV infection that do not express the two major EBV oncogenes, EBNA2 and LMP1. It has been difficult to model how latent EBV infection cooperates with Myc translocation to form BLs, as EBV cannot transform B cells in vitro in the absence of EBNA2 or LMP1. Here we show that human cord blood B cells co-infected with both an EBNA2-deleted EBV mutant and a Myc-expressing retrovirus form BL-like tumors in immunosuppressed mice, while cells infected with EBNA2-deleted EBV alone or the Myc-expressing retrovirus alone do not. These BL-like tumors express many cellular genes over-expressed in human BLs (including genes associated with a germinal center B cell phenotype) and do not express either EBNA2 or LMP1. Furthermore, we show that Myc blocks expression of the highly immunogenic LMP1 protein in BLs by inhibiting the transcriptional activator, STAT3. This new model should be useful for dissecting the mechanisms by which latent EBV infection and Myc translocation cooperatively induce human BLs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. The Role of Natural Killer Cells in the Tumor Immune Microenvironment of EBV-Associated Nasopharyngeal Carcinoma.
- Author
-
Li, Shuzhan, Dai, Wei, Kam, Ngar-Woon, Zhang, Jiali, Lee, Victor H. F., Ren, Xiubao, and Kwong, Dora Lai-Wan
- Subjects
- *
KILLER cells , *T cells , *CELL physiology , *EPSTEIN-Barr virus diseases , *ANTINEOPLASTIC agents , *MAJOR histocompatibility complex , *CARCINOGENESIS , *CYTOKINES , *DISEASE complications ,NASOPHARYNX tumors - Abstract
Simple Summary: Nasopharyngeal carcinoma (NPC) is an epithelial cancer associated with Epstein–Barr virus (EBV) infection. EBV infection contributes to not only the tumorigenesis of NPC but also the formation of a complicated tumor immune microenvironment (TIME) in NPC. Natural killer (NK) cells are lymphoid members of the innate immune system exhibiting both anti-tumor and anti-virus abilities. The cytokine and cellular interaction features of NK cells are distinct from those of CD8+ cytotoxic T cells. This unique characteristic has not been fully described in EBV+ NPC. This review provides an overview of the complicated crosstalk between NK cells and the TIME of EBV+ NPC and potential therapeutic strategies. A new perspective is proposed to direct future exploration. Endemic nasopharyngeal carcinoma (NPC) is closely associated with the Epstein–Barr virus (EBV), which contributes to tumor development and influences the tumor immune microenvironment (TIME) in NPC. Natural killer (NK) cells, as part of the innate immune system, play a crucial role in responding to viral infections and malignant cell transformations. Notably, NK cells possess a unique ability to target tumor cells independent of major histocompatibility complex class I (MHC I) expression. This means that MHC I-deficient tumor cells, which can escape from effective T cell attack, are susceptible to NK-cell-mediated killing. The activation of NK cells is determined by the signals generated through inhibitory and activating receptors expressed on their surface. Understanding the role of NK cells in the complex TIME of EBV+ NPC is of utmost importance. In this review, we provide a comprehensive summary of the current understanding of NK cells in NPC, focusing on their subpopulations, interactions, and cytotoxicity within the TIME. Moreover, we discuss the potential translational therapeutic applications of NK cells in NPC. This review aims to enhance our knowledge of the role of NK cells in NPC and provide valuable insights for future investigations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Primary manifestation of HIV-related Burkitt lymphoma in the oral and maxillofacial regions.
- Author
-
Silva Filho, Nilton José da, Cardoso, Diovana de Melo, Kayahara, Giseli Mitsuy, Xavier-Júnior, José Cândido Caldeira, Cortopassi, Gabriel Macedo, Fonseca, Felipe Paiva, Miyahara, Glauco Issamu, Bernabé, Daniel Galera, and Valente, Vitor Bonetti
- Subjects
- *
DIAGNOSIS of HIV infections , *MOUTH , *MOUTH tumors , *DIFFERENTIAL diagnosis , *HIV-positive persons , *EDEMA , *EPSTEIN-Barr virus diseases , *CELL lines , *LYMPHOID tissue , *LYMPHOPROLIFERATIVE disorders , *B cell lymphoma - Abstract
Burkitt lymphoma (BL) is a subtype of non-Hodgkin lymphoma. It is strongly associated with HIV infection and has a highly aggressive clinical course. The involvement of the maxillofacial region in BL has rarely been reported. A 36-year-old woman with HIV-positive status had painless bilateral swelling of the oral mucosa and middle and lower thirds of the face. Microscopic analysis of the oral lesion revealed an atypical lymphoid infiltrate with a starry sky pattern. The lymphoid cells expressed cluster of differentiation 20, cluster of differentiation 10, B-cell lymphoma 6, and c-Myc; the Ki-67 proliferative index was high. The tumor cells were positive for Epstein-Barr virus. These results led to the diagnosis of HIV-related BL. BL and other immunodeficiency-related lymphoproliferative malignancies may affect the oral and maxillofacial regions and should be included in the differential diagnosis of rapidly expanding swelling in young patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Clinical, Epidemiological, Morphological, and Immunohistochemical Aspects of Nasopharyngeal Carcinoma—4-Year Retrospective Study in the Western Part of Romania.
- Author
-
Marin, Maria Alina, Closca, Raluca-Maria, Marin, Aurel, Rakitovan, Marina, Nicoara, Adrian, Poenaru, Marioara, Militaru, Marius, and Baderca, Flavia
- Subjects
- *
NASOPHARYNX cancer , *LATENT infection , *B cells , *P53 protein , *EPSTEIN-Barr virus diseases ,NASOPHARYNX tumors - Abstract
Nasopharyngeal carcinoma is one of the most common malignant tumors in the head and neck region. The carcinogenesis is a complex process stimulated by many factors. Although the etiological factors and pathogenic mechanisms are not elucidated, the genetic susceptibility, environmental factors, and association with latent infection with Epstein–Barr Virus play an important role. The aim of this study was to present the main clinical and epidemiological data, as well as the morphological aspects and the immunohistochemical profile, of patients with nasopharyngeal carcinoma diagnosed in western Romania. The study was retrospective and included 36 nasopharyngeal carcinomas. The histopathological diagnosis was completed using immunohistochemical reactions for the following antibodies: p63, p53 and p16 protein, cytokeratins (CK) AE1/AE3, CK5, CK7, CK20 and 34βE12, epithelial membrane antigen (EMA), Epstein–Barr virus (EBV), leukocyte common antigen (LCA), CD20, CD4, CD8, CD68, CD117, and CD1a. The squamous malignant component of nasopharyngeal carcinoma presented with positivity for cytokeratins AE1/AE3, CK5, 34βE12, and p63. Undifferentiated nasopharyngeal carcinoma was positive for EMA in 67% of cases, and 28% of cases showed an immunoreaction for CD117 in the malignant epithelial component. Also, the p53 protein was positive in all the cases. One case of undifferentiated nasopharyngeal carcinoma was p16-positive, and two cases were positive for EBV. A peri- and intratumor cellular infiltrate rich in lymphocytes, with a predominance of CD20-positive B lymphocytes, interspersed with T lymphocytes, was observed. The T cells were CD4- and CD8-positive, predominantly intratumoral, and the CD4:CD8 ratio was 1:1 for 75% of the undifferentiated subtype and 89% for differentiated non-keratinized squamous cell carcinoma. All subtypes of nasopharyngeal carcinoma presented with an inflammatory infiltrate with numerous plasma cells, eosinophils, and dendritic cells, presenting as antigen CD1a- and CD68-positive, as well as in CD117-positive mast cells. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Intra-arterial methylprednisolone for pediatric gastrointestinal post-transplant lymphoproliferative disorder.
- Author
-
Jung, Hoyoung, Dhatt, Ravjot, Rassekh, S. Rod, and Heran, Manraj K. S.
- Subjects
- *
LYMPHOPROLIFERATIVE disorders , *GROIN pain , *GASTROINTESTINAL hemorrhage , *METHYLPREDNISOLONE , *GRAFT versus host disease , *KIDNEY transplant complications , *EPSTEIN-Barr virus diseases - Abstract
This article discusses the use of intra-arterial methylprednisolone (IAM) as a treatment for pediatric gastrointestinal post-transplant lymphoproliferative disorder (PTLD). PTLD is a group of lymphoid disorders that occur in transplant recipients, particularly pediatric patients, and is characterized by uncontrolled B cell proliferation. The main treatment for PTLD is reduction of immunosuppression, but this can come with risks. IAM has been shown to be effective in controlling acute gastrointestinal bleeding in steroid-refractory transplant recipients, and this article describes the first use of IAM in a pediatric patient with PTLD. The patient experienced prompt cessation of bleeding and resolution of previous FDG uptake regions on a PET scan, although new regions of FDG uptake were observed. IAM was administered five times without complications. The article suggests that IAM can be a rapid and effective option for managing acute gastrointestinal bleeding in PTLD patients, particularly those on concurrent chemotherapy. Further research is needed to evaluate the utility of IAM in a larger pediatric population. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
30. EBV-Associated Gastric Cancer; An In Situ Hybridization Assay on Tissue Microarray: A Multi-Region Study from Four Major Provinces of Iran.
- Author
-
Abolhasani, Maryam, Mohseni, Ata Ollah, Shakeri, Ramin, Khavanin, Ali, Khajehei, Mehrdad, Omidi, Abbasali, Germizadeh, Bita, Shafigh, Ensiyeh, Naghshvar, Farshad, Fathizadeh, Payam, Taghizadehgan, Leyla, Gharib, Atoosa, Gulley, Margaret L., Dawsey, Sanford M., Malekzadeh, Reza, Rabkin, Charles S., and Vasei, Mohammad
- Subjects
- *
TISSUE arrays , *ADENOCARCINOMA , *STOMACH tumors , *IN situ hybridization , *STATISTICAL significance , *RESEARCH funding , *EPSTEIN-Barr virus diseases , *CHI-squared test , *AGE distribution , *RNA , *HISTOLOGICAL techniques , *RESEARCH , *CANCER cells , *TUMOR classification , *DISEASE complications - Abstract
Background: Gastric cancer is the fourth leading cause of cancer-related deaths in the world. The identification of gastric cancer subtypes related to recognizable microbial agents may play a pivotal role in the targeted prevention and treatment of this cancer. The current study is conducted to define the frequency of Epstein-Barr virus (EBV) infection in gastric cancers of four major provinces, with different incidence rates of gastric cancers, in Iran. Methods: Paraffin blocks of 682 cases of various types of gastric cancer from Tehran, South and North areas of Iran were collected. Twelve tissue microarray (TMA) blocks were constructed from these blocks. Localization of EBV in tumors was assessed by in situ hybridization (ISH) for EBV-encoded RNA (EBER). Chi-squared test was used to evaluate the statistical significance between EBV-associated gastric cancer (EBVaGC) and clinicopathologic tumor characteristics. Results: Fourteen out of 682 cases (2.1%) of gastric adenocarcinoma were EBER-positive. EBER was positive in 8 out of 22 (36.4%) of medullary carcinomas and 6 out of 660 (0.9%) of non-medullary type, which was a statistically significant difference (P < 0.001). The EBVaGCs were more frequent in younger age (P = 0.009) and also showed a trend toward the lower stage of the tumor (P = 0.075). Conclusion: EBV-associated gastric adenocarcinoma has a low prevalence in Iran. This finding can be due to epidemiologic differences in risk factors and exposures, and the low number of gastric medullary carcinomas in the population. It may also be related to gastric tumor heterogeneity not detected with the TMA technique. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Hemophagocytic lymphohistiocytosis—how common and how severe is it as a complication of malaria? Retrospective case series and review of the literature.
- Author
-
Orth, Hans Martin, Wiemer, Dorothea, Schneitler, Sophie, Schönfeld, Andreas, Holtfreter, Martha Charlotte, Gliga, Smaranda, Fuchs, Andre, Pfäfflin, Frieder, Denkinger, Claudia Maria, Kalbitz, Sven, Fritzsche, Carlos, Hübner, Marc P., Trauth, Janina, Jensen, Björn-Erik Ole, Luedde, Tom, and Feldt, Torsten
- Subjects
HEMOPHAGOCYTIC lymphohistiocytosis ,MALARIA ,MULTIPLE organ failure ,EPSTEIN-Barr virus diseases ,SEVERITY of illness index ,EVALUATION of medical care ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,DATA analysis software ,DISEASE complications ,SYMPTOMS - Abstract
Background: Infection-associated secondary hemophagocytic lymphohistiocytosis (sHLH) is a potentially life-threatening hyperinflammatory condition caused by various infectious diseases. Malaria has rarely been described as trigger. The aim of this study is to collect data on frequency, clinical spectrum, and outcome of sHLH induced by malaria. Methods: We collected case numbers on malaria and malaria-associated sHLH from specialized centers in Germany from 2015 to 2022. In addition, we conducted a literature search on published cases of malaria-associated sHLH and systematically analyzed the literature regarding clinical and diagnostic criteria. Results: We obtained data from 13 centers treating 1461 malaria cases with different Plasmodium species, of which 5 patients (0.34%) also were diagnosed with sHLH. The literature search revealed detailed case reports from further 51 patients and case series comprising the description of further 24 patients with malaria-associated sHLH. Most cases (48/80; 60%) were reported from Asia. The median time interval between onset of malaria symptoms and hospital admission was 7 days. Severe complications of sHLH were documented in 36% (20/56) of patients, including two patients with multiple organ failure in our case series. Only 41% (23/56) of patients received specific treatment for sHLH, nevertheless the mortality rate (CFR) of 5% is lower compared to the CFR reported for sHLH triggered by other infectious diseases (e.g., 25% in sHLH due to EBV infection). Conclusion: Malaria-associated sHLH appears to have a comparatively good prognosis but may still represent an underdiagnosed and potentially fatal complication of malaria, especially in resource-poor settings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. PD-1 Blockade-Induced Hemophagocytic Lymphohistiocytosis, a Dilemma Therapeutic Outcome in 2 Patients with CAEBV: A Case Series.
- Author
-
Chen, LeiLei, Wang, Jingshi, and Wang, Zhao
- Subjects
HEMOPHAGOCYTIC lymphohistiocytosis ,PROGRAMMED cell death 1 receptors ,IMMUNE checkpoint inhibitors ,EPSTEIN-Barr virus diseases ,COMBINATION drug therapy - Abstract
Hemophagocytic lymphohistiocytosis (HLH), whether primary or secondary, is a rare and fatal clinical syndrome of uncontrolled immune activation and inflammatory cascade. Immune checkpoint inhibitors (ICIs) induced HLH has no standard diagnostic and treatment guidelines. Early diagnosis and appropriate treatment according to different disease backgrounds are crucial. Herein, we first report 2 cases of patients with chronic active Epstein-Barr virus infection (CAEBV) who developed HLH after the use of sintilimab, a monoclonal antibody against programmed cell death protein 1 (PD-1), and the DEP (liposomal doxorubicin, etoposide, methylprednisolone) chemotherapy regimen in combination with ruxolitinib were used to successfully control the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Do Bed Nets Prevent Cancer?
- Subjects
- *
MALARIA prevention , *MOSQUITO nets , *EPSTEIN-Barr virus diseases , *INSECTICIDES , *B cell lymphoma , *DISEASE risk factors , *DISEASE complications - Abstract
The article examines the association between bed net use and Burkitt lymphoma incidence in children in sub-Saharan Africa. It reviews studies before and after the widespread use of insecticide-treated bed nets and suggests that while bed net use reduces malaria risk. It also correlates with a lower incidence of Burkitt lymphoma, emphasizing the importance of malaria prevention strategies in reducing childhood cancer risk.
- Published
- 2024
34. Acalculous cholecystitis in a young adult with scrub typhus: A case report and epidemiology of scrub typhus in the Maldives
- Author
-
Imad, Hisham Ahmed, Ali, Aishath Azna, Nahuza, Mariyam, Gurung, Rajan, Ubaid, Abdulla, Maeesha, Aishath, Didi, Sariu Ali, Dey, Rajib Kumar, Hilmy, Abdullah Isneen, Hareera, Aishath, Afzal, Ibrahim, Matsee, Wasin, Nguitragool, Wang, Nakayama, Emi E, and Shioda, Tatsuo
- Published
- 2021
35. Assessment of the Diagnostic Performance of Fully Automated Hepatitis E Virus (HEV) Antibody Tests.
- Author
-
Eichhorn, Anna, Neumann, Franziska, Bäumler, Carina, Gutsmann, Imke, Grobe, Olaf, Schlüter, Frieda, Müller, Sina, and Krumbholz, Andi
- Subjects
- *
HEPATITIS E virus , *ANTIBODY titer , *EPSTEIN-Barr virus diseases , *CHEMILUMINESCENCE immunoassay , *CYTOMEGALOVIRUS diseases - Abstract
The detection of anti-hepatitis E virus (HEV) antibodies contributes to the diagnosis of hepatitis E. The diagnostic suitability of two automated chemiluminescence immunoassays (CLIAs, LIAISON® MUREX Anti-HEV IgG/Anti-HEV IgM test, DiaSorin) was assessed by comparison with the results of a combination of enzyme immunoassays and immunoblots (recomWell HEV IgG/IgM ELISA, recomLine HEV IgG/IgM, MIKROGEN). Samples with a deviating result were analyzed with the WANTAI ELISAs. Compared to the recomWell ELISAs, the Anti-HEV IgG CLIA had a percentage overall agreement (POA) of 100% (149/149; 95% CI: 97.5–100%) and the Anti-HEV IgM CLIA had a POA of 83.3% (85/102; 95% CI: 74.9–89.3%); considering the recomLine HEV IgM results, the POA was 71.7% (38/53; 95% CI: 58.4–82%). The WANTAI test confirmed 52.9% (9/17) of negative CLIA IgMs; HEV RNA was not detectable. Since acute infection with the Epstein–Barr virus (EBV) or human cytomegalovirus (CMV) may influence the results of other serological assays, HEV antibodies were examined in 17 EBV and 2 CMV patients: One had an isolated and probably unspecific HEV IgM in the CLIA, as HEV RNA was not detectable. Both CLIAs are well suited for HEV diagnostics, but isolated IgM should be confirmed. An acute EBV/CMV infection can influence HEV serodiagnostics. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Impact of plasma Epstein–Barr virus DNA in posttreatment nasopharyngeal carcinoma patients after SARS-CoV-2 infection.
- Author
-
Lin, Cheng, Li, Meifang, Lin, Yingying, Zhang, Yu, Xu, Hanchuan, Chen, Bijuan, Yan, Xia, and Xu, Yun
- Subjects
- *
CANCER relapse , *RECEIVER operating characteristic curves , *RESEARCH funding , *EPSTEIN-Barr virus diseases , *DNA , *NASOPHARYNX cancer , *GENETIC mutation , *CONFIDENCE intervals , *COVID-19 , *PATIENT aftercare , *PATIENTS' attitudes , *SENSITIVITY & specificity (Statistics) - Abstract
Background: Nasopharyngeal carcinoma (NPC) is prevalent in southern China. EBV DNA is the most useful biomarker in NPC. However, the value of EBV DNA in posttreatment NPC patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains unclear. Methods: Sixty-four eligible NPC patients were enrolled between December 2022 and February 2023. Patients who met the following criteria were included: had non-metastatic NPC, completed radical treatment, were first firstly infected with SARS-CoV-2 and their EBV DNA changed from undetectable to detectable. Results: At the end of follow-up, 81.25% (52/64) of patients were confirmed not to relapse with undetectable EBV DNA (no-relapse). In addition, 18.75% (12/64) of patients experienced relapse with consistent detection of EBV DNA (yes-relapse). For all 64 patients, the average time from diagnosis of coronavirus disease 2019 (COVID-19) to detection of detectable EBV DNA was 35.41 days (2 to 139 days). For 52 no-relapse patients, the average time from EBV DNA changing from detectable to undetectable was 63.12 days (6 to 147 days). The levels of EBV DNA were greater in yes-relapse patients than that in no-relapse patients, and the average of EBV DNA levels were 1216 copies/ml and 53.18 copies/ml, respectively. Using 62.3 copies/mL as the threshold, the area under the curve for EBV DNA was 0.88 for distinguishing yes-relapse patients from no-relapse patients. The sensitivity and specificity were 81.97% (95% CI 0.71–0.95) and 86.67% (95% CI 0.70–0.95), respectively. Conclusion: For NPC patients infected with SARS-CoV-2, EBV DNA alone is insufficient for monitoring relapse after radical therapy. Long-term follow-up and underlying mechanistic investigations of EBV DNA changes are urgently needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Acalculous Cholecystitis as a Complication of Primary Epstein-Barr Virus Infection: A Case-Based Scoping Review of the Literature.
- Author
-
Tsiakalos, Aristotelis, Schinas, Georgios, Karatzaferis, Aggelos, Rigopoulos, Emmanouil Angelos, Pappas, Christos, Polyzou, Eleni, Dimopoulou, Effrosyni, Dimopoulos, George, and Akinosoglou, Karolina
- Subjects
- *
EPSTEIN-Barr virus diseases , *EPSTEIN-Barr virus , *ACALCULOUS cholecystitis , *LITERATURE reviews , *INFECTION , *SYMPTOMS - Abstract
Primary Epstein-Barr virus (EBV) infection manifests with diverse clinical symptoms, occasionally resulting in severe complications. This scoping review investigates the rare occurrence of acute acalculous cholecystitis (AAC) in the context of primary EBV infection, with a focus on understanding its prevalence, clinical features, and underlying mechanisms. The study also explores EBV infection association with Gilbert syndrome, a condition that potentially exacerbates the clinical picture. Additionally, a case report of an 18-year-old female presenting with AAC and ascites secondary to EBV infection enhances the review. A comprehensive literature review was conducted, analyzing reported cases of AAC secondary to EBV infection. This involved examining patient demographics, clinical presentations, laboratory findings, and outcomes. The search yielded 44 cases, predominantly affecting young females. Common clinical features included fever, cervical lymphadenopathy, tonsillitis/pharyngitis, and splenomegaly. Laboratory findings highlighted significant hepatic involvement. The review also noted a potential link between AAC in EBV infection and Gilbert syndrome, particularly in cases with abnormal bilirubin levels. AAC is a rare but significant complication of primary EBV infection, primarily observed in young females, and may be associated with Gilbert syndrome. This comprehensive review underscores the need for heightened clinical awareness and timely diagnosis to manage this complication effectively. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Gene–environment interactions: Epstein–Barr virus infection and risk of pediatric-onset multiple sclerosis.
- Author
-
Ziaei, Amin, Solomon, Olivia, Casper, T Charles, Waltz, Michael, Weinstock-Guttman, Bianca, Aaen, Greg, Wheeler, Yolanda, Graves, Jennifer, Benson, Leslie, Gorman, Mark, Rensel, Mary, Mar, Soe, Lotze, Tim, Greenberg, Benjamin, Chitnis, Tanuja, Waldman, Amy T, Krupp, Lauren, James, Judith A, Hart, Janace, and Barcellos, Lisa F
- Subjects
- *
EPSTEIN-Barr virus diseases , *MULTIPLE sclerosis , *HLA histocompatibility antigens , *EPSTEIN-Barr virus , *LOGISTIC regression analysis - Abstract
Background and Objective: Prior Epstein–Barr virus (EBV) infection is associated with an increased risk of pediatric-onset multiple sclerosis (POMS) and adult-onset multiple sclerosis (MS). It has been challenging to elucidate the biological mechanisms underlying this association. We examined the interactions between candidate human leukocyte antigen (HLA) and non-HLA variants and childhood EBV infection as it may provide mechanistic insights into EBV-associated MS. Methods: Cases and controls were enrolled in the Environmental and Genetic Risk Factors for Pediatric MS study of the US Network of Pediatric MS Centers. Participants were categorized as seropositive and seronegative for EBV-viral capsid antigen (VCA). The association between prior EBV infection and having POMS was estimated with logistic regression. Interactions between EBV serostatus, major HLA MS risk factors, and non-HLA POMS risk variants associated with response to EBV infection were also evaluated with logistic regression. Models were adjusted for sex, age, genetic ancestry, and the mother's education. Additive interactions were calculated using relative risk due to interaction (RERI) and attributable proportions (APs). Results: A total of 473 POMS cases and 702 controls contributed to the analyses. Anti-VCA seropositivity was significantly higher in POMS cases compared to controls (94.6% vs 60.7%, p < 0.001). There was evidence for additive interaction between childhood EBV infection and the presence of the HLA-DRB1*15 allele (RERI = 10.25, 95% confidence interval (CI) = 3.78 to 16.72; AP = 0.61, 95% CI = 0.47 to 0.75). There was evidence for multiplicative interaction (p < 0.05) between childhood EBV infection and the presence of DRB1*15 alleles (odds ratio (OR) = 3.43, 95% CI = 1.06 to 11.07). Among the pediatric MS variants also associated with EBV infection, we detected evidence for additive interaction (p = 0.02) between prior EBV infection and the presence of the GG genotype in risk variant (rs2255214) within CD86 (AP = 0.30, 95% CI = 0.03 to 0.58). Conclusion: We report evidence for interactions between childhood EBV infection and DRB1*15 and the GG genotype of CD86 POMS risk variant. Our results suggest an important role of antigen-presenting cells (APCs) in EBV-associated POMS risk. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Epigenetic Mechanisms in Latent Epstein-Barr Virus Infection and Associated Cancers.
- Author
-
Torne, Atharva S. and Robertson, Erle S.
- Subjects
- *
EPITHELIAL cells , *EPIGENOMICS , *EPSTEIN-Barr virus diseases , *MICRORNA , *LATENT infection , *LYMPHOMAS , *DNA methylation , *AUTOIMMUNE diseases , *MONONUCLEOSIS , *TUMORS , *NASOPHARYNX cancer , *GENOMES , *DISEASE progression - Abstract
Simple Summary: Epstein–Barr virus (EBV) was first isolated in 1964 and has since become an important human tumor virus. With an estimated 90% of the human population infected with the virus, EBV has also been shown to cause several types of cancers. The virus has evolved numerous epigenetic mechanisms by which it can affect its host and contribute to the development and progression of cancer. In this review, we introduce four prominent epigenetic regulatory mechanisms that result in host-virus interactions for the purpose of EBV infection, persistence, and contribution to EBV-associated diseases. We then look at how epigenetic profiles of the host are altered in EBV-associated cancers to understand the precise ways EBV interacts with its host to cause disease. This work explores the viral epigenetics of EBV and provides insights into the knowns and unknowns of research into EBV and EBV-associated cancers. The Epstein–Barr Virus (EBV) is a double-stranded DNA-based human tumor virus that was first isolated in 1964 from lymphoma biopsies. Since its initial discovery, EBV has been identified as a major contributor to numerous cancers and chronic autoimmune disorders. The virus is particularly efficient at infecting B-cells but can also infect epithelial cells, utilizing an array of epigenetic strategies to establish long-term latent infection. The association with histone modifications, alteration of DNA methylation patterns in host and viral genomes, and microRNA targeting of host cell factors are core epigenetic strategies that drive interactions between host and virus, which are necessary for viral persistence and progression of EBV-associated diseases. Therefore, understanding epigenetic regulation and its role in post-entry viral dynamics is an elusive area of EBV research. Here, we present current outlooks of EBV epigenetic regulation as it pertains to viral interactions with its host during latent infection and its propensity to induce tumorigenesis. We review the important epigenetic regulators of EBV latency and explore how the strategies involved during latent infection drive differential epigenetic profiles and host-virus interactions in EBV-associated cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Activation of Epstein–Barr Virus' Lytic Cycle in Nasopharyngeal Carcinoma Cells by NEO212, a Conjugate of Perillyl Alcohol and Temozolomide.
- Author
-
Hartman-Houstman, Hannah, Swenson, Steve, Minea, Radu O., Sinha, Uttam K., Chiang, Ming-Fu, Chen, Thomas C., and Schönthal, Axel H.
- Subjects
- *
RISK assessment , *IN vitro studies , *RESEARCH funding , *EPSTEIN-Barr virus diseases , *TEMOZOLOMIDE , *BRAIN , *ENDOPLASMIC reticulum , *GANCICLOVIR , *IN vivo studies , *TUMOR markers , *DESCRIPTIVE statistics , *CELL lines , *METASTASIS , *MICE , *REACTIVE oxygen species , *ANIMAL experimentation , *NASOPHARYNX cancer , *ALCOHOLS (Chemical class) , *DISEASE risk factors , *DISEASE complications - Abstract
Simple Summary: Nasopharyngeal carcinoma (NPC) is a cancer that is frequently associated with Epstein–Barr virus (EBV) infection, and this virus is thought to play a role in NPC development and malignant growth. Within tumor cells, the virus generally remains in a latent stage that supports cell survival and stimulates tumor growth. However, it has been postulated that it might be beneficial as part of cancer therapy to coax the virus out of its latent stage and into a lytic mode, which would result in tumor cell killing. A few agents are known to accomplish this switch, but their clinical success so far has been mixed. We are developing a novel compound, NEO212, that has shown anticancer activity in several preclinical tumor models. Here, in this report, we demonstrate that it is able to coax EBV into its lytic cycle, resulting in NPC cell death. We propose that NEO212 should be investigated further for its potential clinical usefulness as a therapeutic agent for NPC. The Epstein–Barr virus (EBV) is accepted as a primary risk factor for certain nasopharyngeal carcinoma (NPC) subtypes, where the virus persists in a latent stage which is thought to contribute to tumorigenesis. Current treatments are sub-optimal, and recurrence occurs in many cases. An alternative therapeutic concept is aimed at triggering the lytic cycle of EBV selectively in tumor cells as a means to add clinical benefit. While compounds able to stimulate the lytic cascade have been identified, their clinical application so far has been limited. We are developing a novel anticancer molecule, NEO212, that was generated by covalent conjugation of the alkylating agent temozolomide (TMZ) to the naturally occurring monoterpene perillyl alcohol (POH). In the current study, we investigated its potential to trigger the lytic cycle of EBV in NPC cells in vitro and in vivo. We used the established C666.1 cell line and primary patient cells derived from the brain metastasis of a patient with NPC, both of which harbored latent EBV. Upon treatment with NEO212, there was an increase in EBV proteins Zta and Ea-D, key markers of the lytic cycle, along with increased levels of CCAAT/enhancer-binding protein homologous protein (CHOP), a marker of endoplasmic reticulum (ER) stress, followed by the activation of caspases. These effects could also be confirmed in tumor tissue from mice implanted with C666.1 cells. Towards a mechanistic understanding of these events, we used siRNA-mediated knockdown of CHOP and inclusion of anti-oxidant compounds. Both approaches blocked lytic cycle induction by NEO212. Therefore, we established a sequence of events, where NEO212 caused reactive oxygen species (ROS) production, which triggered ER stress and elevated the levels of CHOP, which was required to stimulate the lytic cascade of EBV. Inclusion of the antiviral agent ganciclovir synergistically enhanced the cytotoxic impact of NEO212, pointing to a potential combination treatment for EBV-positive cancers which should be explored further. Overall, our study establishes NEO212 as a novel agent able to stimulate EBV's lytic cycle in NPC tumors, with implications for other virus-associated cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Precision Medicine for Nasopharyngeal Cancer—A Review of Current Prognostic Strategies.
- Author
-
Suryani, Luvita, Lee, Hazel P. Y., Teo, Wei Keat, Chin, Zhi Kang, Loh, Kwok Seng, and Tay, Joshua K.
- Subjects
- *
RISK assessment , *PREDICTIVE tests , *PREDICTION models , *DIFFUSION of innovations , *CANCER invasiveness , *EPSTEIN-Barr virus diseases , *MICRORNA , *RADIOMICS , *METASTASIS , *RNA , *NASOPHARYNX cancer , *INDIVIDUALIZED medicine - Abstract
Simple Summary: The current standard of care for nasopharyngeal carcinoma (NPC) is predominantly guided by the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) tumour-node-metastasis (TNM) staging system. This review aims to discuss the current strategies and development of new technologies to optimise NPC patients' stratification to ultimately provide better patient management and more targeted therapy. Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV) driven malignancy arising from the nasopharyngeal epithelium. Current treatment strategies depend on the clinical stage of the disease, including the extent of the primary tumour, the extent of nodal disease, and the presence of distant metastasis. With the close association of EBV infection with NPC development, EBV biomarkers have shown promise in predicting treatment outcomes. Among the omic technologies, RNA and miRNA signatures have been widely studied, showing promising results in the research setting to predict treatment response. The transformation of radiology images into measurable features has facilitated the use of radiomics to generate predictive models for better prognostication and treatment selection. Nonetheless, much of this work remains in the research realm, and challenges remain in clinical implementation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Epidemiological characteristics of Epstein‐Barr virus infection in children and distribution of disease spectrum in hospitalized patients in shandong province.
- Author
-
Wu, Dan, Wang, Juan, Zeng, Qian, Wang, Ling, and Lv, Xin
- Subjects
EPSTEIN-Barr virus diseases ,JUVENILE diseases ,HOSPITAL patients ,SYMPTOMS ,EPSTEIN-Barr virus - Abstract
This study aims to investigate the epidemiological characteristics of Epstein‐Barr virus (EBV) infection in children and the distribution of disease spectrum in hospitalized patients in Shandong Province. A retrospective analysis was conducted on the clinical data of children with EBV infection admitted to hospitals in Shandong Province from January 2022 to December 2022. The epidemiological characteristics, including age, gender, and clinical manifestations, were analyzed. The detection rate of EBV antibodies and the seropositivity rates of different antibodies were also examined. A total of 7124 children with EBV infection were included in this study, with an average age of 7.5 years. The male‐to‐female ratio was 1.43:1. Among the patients, the positive detection rate of EBV antibodies was 78.40%. The seropositivity rate of Epstein‐Barr viral capsid antigen‐Immunoglobin G antibodies was 57.09%. The highest incidence of EBV infection was observed in the age group 36−72 months. The urban positive rate was higher than that in rural areas. EBV infection in children in Shandong Province exhibits specific epidemiological characteristics, with a higher incidence in the age group of 36−72 months. Fever, sore throat, and fatigue are the main clinical manifestations. The detection rate of EBV antibodies is relatively high among hospitalized patients. These findings provide valuable information for controlling the transmission of children with suspected Epstein‐Barr virus infection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Tandem Mass Tag-Based Proteomic Analysis of Normal and Degenerated Human Intervertebral Discs.
- Author
-
Fu, Yang, Huang, Xiao-Qin, Qu, Hang-Bo, Ge, Yan Zhi, and Ru, Xuan-Liang
- Subjects
INTERVERTEBRAL disk ,LIQUID chromatography-mass spectrometry ,NON-alcoholic fatty liver disease ,EPSTEIN-Barr virus diseases ,PROTEOMICS - Abstract
Background: Intervertebral disc degeneration (IVDD) is the main cause of low back pain (LBP), but the specific regulatory factors, pathways and specific molecular mechanisms remain unclear. Methods: We identified and quantitatively analyzed Pfirrmann Grade II (n=3) and Pfirrmann Grade IV (n=3) pulposus samples via MRI. The differential abundance of proteins in the samples was determined and quantitatively analyzed by relative and absolute quantitative analysis of the isotope marker levels combined with the liquid chromatography–tandem mass spectrometry (LC‒MSMS/MS). Results: A total of 70 proteins (30 significantly increased proteins (> 1.2-fold change) and 40 significantly decreased proteins (< 0.8-fold change)) showed different levels among the groups. Kyoto Encyclopedia of Genes and Genomes and Gene Ontology (GO) enrichment analyses and Western blot analysis showed that CYCS, RAC1, and PSMD14 may play important roles in IVDD and that Epstein‒Barr virus infection, viral myocarditis, colorectal cancer, nonalcoholic fatty liver disease (NAFLD) and amyotrophic lateral sclerosis (ALS) are the main pathways involved in IVDD. Conclusion: CYCS, RAC1 and PSMD14 may play important roles in IVDD, and Epstein‒Barr virus infection, viral myocarditis, colorectal cancer, NAFLD and ALS may be the main pathways involved in IVDD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Cerebellar encephalitis associated with anti-mGluR1 antibodies: a case report and comprehensive literature review.
- Author
-
Xue Chen, Yanan Chen, Lu Di, Na Liu, Ting Liu, Yun Cai, and Weiying Di
- Subjects
VIRAL encephalitis ,LITERATURE reviews ,LEUKOCYTE count ,ENCEPHALITIS ,EPSTEIN-Barr virus diseases ,GLUTAMATE receptors - Abstract
Anti-metabotropic glutamate receptor 1 encephalitis is an uncommon autoimmune condition characterized by a subacute onset of cerebellar syndrome. Frequently, it also manifests as sleep disorders and cognitive or behavioral changes. While immunotherapy is the primary treatment approach, the disease remains poorly understood. Herein, we present a case of anti-metabotropic glutamate receptor 1 encephalitis, highlighting its primary cerebellar syndrome manifestation. The first magnetic resonance imaging scan showed no obvious abnormality. Lumbar puncture showed increased cerebrospinal fluid pressure, increased white blood cell count and protein level. The next-generation sequencing of cerebrospinal fluid showed Epstein-Barr virus infection, and the patient was diagnosed with viral cerebellar encephalitis. However, antiviral therapy was ineffective. Finally, anti-metabotropic glutamate receptor 1 was measured at 1:1,000, and the patient was definitely diagnosed with anti-metabotropic glutamate receptor 1 encephalitis. Therefore, clinicians should pay attention to such diseases to avoid misdiagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Epstein-Barr Virus Promotes Tumorigenicity and Worsens Hodgkin Lymphoma Prognosis by Activating JAK/STAT and NF-?B Signaling Pathways.
- Author
-
Alabiad, Mohamed Ali, Said, Warda M. M., Faraj Saad, Rema H., Balata, Rawda, Mahmoud, Asmaa A., Metwally, Elsayed Anany, Shalaby, Amany Mohamed, Samy, Walaa, Yehia, Ahmed M., Yahia, Amar Ibrahim Omar, Alorini, Mohammed, and Abdelrahman, Doaa I.
- Subjects
- *
HODGKIN'S disease , *CANCER invasiveness , *NF-kappa B , *JANUS kinases , *CELLULAR signal transduction , *GENE expression , *COMPARATIVE studies , *MESSENGER RNA , *CHI-squared test , *KAPLAN-Meier estimator , *DESCRIPTIVE statistics , *EPSTEIN-Barr virus diseases , *EPIGENOMICS , *LONGITUDINAL method - Abstract
Background: Epstein-Barr virus (EBV) is detected in 40% of patients with Hodgkin lymphoma (HL). During latency, EBV induces epigenetic alterations to the host genome and decreases the expression of pro-apoptotic proteins. The present study aimed to evaluate the expression levels of mRNA molecules and the end product of proteins for the JAK/STAT and NF-κB pathways, and their association with clinicopathological and prognostic parameters in patients with EBV-positive and -negative classical Hodgkin lymphoma (CHL). Methods: A prospective cohort study was conducted from 2017 to 2022 at the Faculty of Medicine, Zagazig University Hospital (Zagazig, Egypt). Biopsy samples of 64 patients with CHL were divided into EBV-positive and EBV-negative groups. The expression levels of mRNA molecules (JAK2, STAT1, IRF-1, PD-L1, IFN-γ, NF-κB, Bcl-xL, COX-2) and the end product of proteins (PD-L1, Bcl-xL, COX-2) were determined and compared with clinicopathological and prognostic parameters. Data were analyzed using the Chi square test and Kaplan-Meier estimate. Results: EBV-positive CHL patients were significantly associated with positive expression of mRNAs molecules (P<0.001) and the end product of proteins (P<0.001) for the JAK/STAT and NF-κB pathways, B-symptoms (P=0.022), extra-nodal involvement (P=0.017), and advanced stage of CHL (P=0.018). These patients were more susceptible to cancer progression, higher incidence of relapse (P=0.008), poor disease-free survival rate (P=0.013), poor overall survival rate (P=0.028), and higher mortality rate (P=0.015). Conclusion: Through the activation of JAK/STAT and NF-κB signaling pathways, EBV-positive CHL is associated with poor clinicopathological parameters, higher incidence of disease progression, relapse, and poor overall survival. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. TPGS-b-PBAE Copolymer-Based Polyplex Nanoparticles for Gene Delivery and Transfection In Vivo and In Vitro.
- Author
-
Ding, Jiahui, Zhang, Handan, Dai, Tianli, Gao, Xueqin, Yin, Zhongyuan, Wang, Qiong, Long, Mengqi, and Tan, Songwei
- Subjects
- *
GENE transfection , *CATIONIC polymers , *GENOME editing , *MEMBRANE proteins , *GREEN fluorescent protein , *EPSTEIN-Barr virus diseases - Abstract
Poly (β-amino ester) (PBAE) is an exceptional non-viral vector that is widely used in gene delivery, owing to its exceptional biocompatibility, easy synthesis, and cost-effectiveness. However, it carries a high surface positive charge that may cause cytotoxicity. Therefore, hydrophilic d-α-tocopherol polyethylene glycol succinate (TPGS) was copolymerised with PBAE to increase the biocompatibility and to decrease the potential cytotoxicity of the cationic polymer-DNA plasmid polyplex nanoparticles (NPs) formed through electrostatic forces between the polymer and DNA. TPGS-b-PBAE (TBP) copolymers with varying feeding molar ratios were synthesised to obtain products of different molecular weights. Their gene transfection efficiency was subsequently evaluated in HEK 293T cells using green fluorescent protein plasmid (GFP) as the model because free GFP is unable to easily pass through the cell membrane and then express as a protein. The particle size, ζ-potential, and morphology of the TBP2-GFP polyplex NPs were characterised, and plasmid incorporation was confirmed through gel retardation assays. The TBP2-GFP polyplex NPs effectively transfected multiple cells with low cytotoxicity, including HEK 293T, HeLa, Me180, SiHa, SCC-7 and C666-1 cells. We constructed a MUC2 (Mucin2)-targeting CRISPR/cas9 gene editing system in HEK 293T cells, with gene disruption supported by oligodeoxynucleotide (ODN) insertion in vitro. Additionally, we developed an LMP1 (latent membrane protein 1)-targeting CRISPR/cas9 gene editing system in LMP1-overexpressing SCC7 cells, which was designed to cleave fragments expressing the LMP1 protein (related to Epstein–Barr virus infection) and thus to inhibit the growth of the cells in vivo. As evidenced by in vitro and in vivo experiments, this system has great potential for gene therapy applications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Cancer and HIV: The Molecular Mechanisms of the Deadly Duo.
- Author
-
Omar, Aadilah, Marques, Natasia, and Crawford, Nicole
- Subjects
- *
HIV infection complications , *TUMOR risk factors , *HIV-positive persons , *CYTOKINES , *TELOMERES , *IMMUNOLOGICAL tolerance , *DISEASE progression , *SOCIAL determinants of health , *VIRAL proteins , *VIRAL load , *CANCER invasiveness , *INFLAMMATION , *IMMUNOCOMPROMISED patients , *ANTIRETROVIRAL agents , *B cell lymphoma , *KAPOSI'S sarcoma , *CELLULAR signal transduction , *MIXED infections , *PAPILLOMAVIRUS diseases , *TUMOR suppressor genes , *DISEASE susceptibility , *AIDS-related opportunistic infections , *TUMOR markers , *HEALTH equity , *AIDS , *NON-Hodgkin's lymphoma , *EPSTEIN-Barr virus diseases , *DISEASE risk factors , *DISEASE complications ,CERVIX uteri tumors - Abstract
Simple Summary: Following infection with HIV, individuals are immunocompromised. Their weakened immune system puts them at a higher risk of certain cancers like Kaposi sarcoma and lymphoma. Even with antiretroviral therapy for HIV infection, these cancers remain common in developing countries, while in developed countries, there is a decline in some cancers but an increase in deaths from others. This review explores why these cancers happen in people with HIV and finds that the current treatment is not enough to prevent them. Understanding these reasons is crucial to improving the diagnosis and treatment of both HIV and its associated cancers, highlighting the need for more research to tackle this ongoing health issue. The immune deficiency associated with human immunodeficiency virus (HIV) infection causes a distinct increased risk of developing certain cancer types. Kaposi sarcoma (KS), invasive cervical cancer and non-Hodgkin's lymphoma (NHL) are the prominent malignancies that manifest as a result of opportunistic viral infections in patients with advanced HIV infection. Despite the implementation of antiretroviral therapy (ART), the prevalence of these acquired immunodeficiency syndrome (AIDS)-defining malignancies (ADMs) remains high in developing countries. In contrast, developed countries have experienced a steady decline in the occurrence of these cancer types. However, there has been an increased mortality rate attributed to non-ADMs. Here, we provide a review of the molecular mechanisms that are responsible for the development of ADMs and non-ADMs which occur in HIV-infected individuals. It is evident that ART alone is not sufficient to fully mitigate the potential for ADMs and non-ADMs in HIV-infected individuals. To enhance the diagnosis and treatment of both HIV and malignancies, a thorough comprehension of the mechanisms driving the development of such cancers is imperative. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. A Focused Review of Epstein-Barr Virus Infections and PTLD in Pediatric Transplant Recipients: Guidance From the IPTA and ECIL Guidelines.
- Author
-
Yamada, Masaki, L'Huillier, Arnaud G, and Green, Michael
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *INTRAVENOUS immunoglobulins , *CHEMOPREVENTION , *PATIENTS , *TRANSPLANTATION of organs, tissues, etc. , *EPSTEIN-Barr virus diseases , *PEDIATRICS , *SURGICAL complications , *MONOCLONAL antibodies , *ANTIVIRAL agents , *LYMPHOPROLIFERATIVE disorders - Abstract
Epstein-Barr Virus (EBV) diseases, including EBV-associated post-transplant lymphoproliferative disorder (PTLD) remain important causes of morbidity and mortality in children undergoing solid organ transplantation (SOT) and hematopoietic cell transplantation (HCT). Despite progress in the prevention of EBV disease including PTLD (EBV/PTLD) in HCT, key questions in the prevention, and management of these infectious complications remain unanswered. The goal of this manuscript is to highlight key points and recommendations derived from the consensus guidelines published by the International Pediatric Transplant Association and the European Conference on Infections in Leukemia for children undergoing SOT and HCT, respectively. Additionally, we provide background and guidance on the use of EBV viral load measurement in the prevention and management of these children. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Ceramide promotes lytic reactivation of Epstein-Barr virus in gastric carcinoma.
- Author
-
Jun Yeob Kim, Young Jin Min, Min-Hyeok Lee, Yea Rim An, Ashktorab, Hassan, Smoot, Duane T., Sung Won Kwon, and Suk Kyeong Lee
- Subjects
- *
EPSTEIN-Barr virus , *STOMACH cancer , *CERAMIDES , *VIRUS reactivation , *EPSTEIN-Barr virus diseases - Abstract
Epstein-Barr virus (EBV) has a lifelong latency period after initial infection. Rarely, however, when the EBV immediate early gene BZLF1 is expressed by a specific stimulus, the virus switches to the lytic cycle to produce progeny viruses. We found that EBV infection reduced levels of various ceramide species in gastric cancer cells. As ceramide is a bioactive lipid implicated in the infection of various viruses, we assessed the effect of ceramide on the EBV lytic cycle. Treatment with C6-ceramide (C6-Cer) induced an increase in the endogenous ceramide pool and increased production of the viral product as well as BZLF1 expression. Treatment with the ceramidase inhibitor ceranib-2 induced EBV lytic replication with an increase in the endogenous ceramide pool. The glucosylceramide synthase inhibitor Genz-123346 inhibited C6-Cer-induced lytic replication. C6-Cer induced extracellular signal-regulated kinase 1/2 (ERK1/2) and CREB phosphorylation, c-JUN expression, and accumulation of the autophagosome marker LC3B. Treatment with MEK1/2 inhibitor U0126, siERK1&2, or siCREB suppressed C6-Cer-induced EBV lytic replication and autophagy initiation. In contrast, siJUN transfection had no impact on BZLF1 expression. The use of 3-methyladenine (3-MA), an inhibitor targeting class III phosphoinositide 3-kinases (PI3Ks) to inhibit autophagy initiation, resulted in reduced beclin-1 expression, along with suppressed C6-Cer-induced BZLF1 expression and LC3B accumulation. Chloroquine, an inhibitor of autophagosome-lysosome fusion, increased BZLF1 protein intensity and LC3B accumulation. However, siLC3B transfection had minimal effect on BZLF1 expression. The results suggest the significance of ceramide-related sphingolipid metabolism in controlling EBV latency, highlighting the potential use of drugs targeting sphingolipid metabolism for treating EBV-positive gastric cancer. IMPORTANCE Epstein-Barr virus remains dormant in the host cell but occasionally switches to the lytic cycle when stimulated. However, the exact molecular mechanism of this lytic induction is not well understood. In this study, we demonstrate that Epstein-Barr virus infection leads to a reduction in ceramide levels. Additionally, the restoration of ceramide levels triggers lytic replication of Epstein-Barr virus with increase in phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) and CREB. Our study suggests that the Epstein-Barr virus can inhibit lytic replication and remain latent through reduction of host cell ceramide levels. This study reports the regulation of lytic replication by ceramide in Epstein-Barr virus-positive gastric cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Ulcus Vulvae Acutum Lipschütz--UVAL: case series at a Swiss university hospital emergency room.
- Author
-
Guareschi, Vittoria, Mathevet, Patrice, and Jacot-Guillarmod, Martine
- Subjects
ULCER diagnosis ,FEMALE reproductive organ diseases ,BIOPSY ,NONSTEROIDAL anti-inflammatory agents ,MEDICAL logic ,ULCERS ,ACADEMIC medical centers ,ACUTE diseases ,DIFFERENTIAL diagnosis ,EPSTEIN-Barr virus diseases ,GYNECOLOGIC care ,HOSPITAL emergency services ,RETROSPECTIVE studies ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,ORAL drug administration ,PHARMACEUTICAL gels ,BEHCET'S disease ,LONGITUDINAL method ,CLINICAL pathology ,RESEARCH methodology ,SEROLOGY ,HERPESVIRUS diseases ,VULVA ,ACETAMINOPHEN ,LIDOCAINE ,PATIENT aftercare ,ALGORITHMS ,SYMPTOMS - Abstract
Background: Ulcus Vulvae Acutum Lipschütz (UVAL) is a largely unknown disease with a broad and complex differential diagnosis. Objectives: To provide a description of the main characteristics of UVAL, determine the most appropriate diagnostic process and describe the current therapeutic approach. Methods: We designed a retrospective, descriptive cohort study using the gynecological-ER database of our institution. Inclusion criteria: female patients aged between 10 and 20 years old with suspicion of a UVAL diagnosis at CHUV's gynecological ER. Data extraction: epidemiological characteristics, clinical presentation, laboratory tests, established diagnostics, treatment, and ulcer outcomes. Results: 15 patients were included for the analysis; average age: 15 years old; 60% of patients were virgo at the time of ulcer onset; all patients had at least one flu-like symptom concomitant with the vulvar lesion; the most-performed serology was for EBV and acute disease was present in only one patient; for diagnostic purposes two biopsies were performed with both inconclusive histopathology analysis; the main prescribed treatments were: oral NSAIDs, Paracetamol, and Lidocaine gel; 93% of cases presented signs of regression; the average follow-up time was 10 days. The diagnostic algorithm of Sadoghi et al: 10 out of 15 cases were retrospectively diagnosed with UVAL by the algorithm; half were diagnosed with UVAL, and the other half received a diagnosis of "ulcers of unknown origin" at the time of the gynecological ER visit. Conclusions: We highly recommend the diagnostic and therapeutic algorithms developed by Sadoghi et al. as valuable tools to guide clinical reasoning and, consequently, improve acute vulvar ulcers management. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.